Bioventus (NYSE:BVS) Updates FY 2025 Earnings Guidance

Bioventus (NYSE:BVS) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.640-0.680 for the period, compared to the consensus EPS estimate of 0.660. The company issued revenue guidance of $560.0 million-$570.0 million, compared to the consensus revenue estimate of $564.9 million.

Bioventus Stock Down 4.2 %

Bioventus stock opened at $7.03 on Tuesday. The firm has a market capitalization of $576.07 million, a price-to-earnings ratio of -11.52 and a beta of 0.95. The firm’s fifty day moving average price is $8.68 and its two-hundred day moving average price is $10.23. Bioventus has a 1-year low of $3.95 and a 1-year high of $14.38. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85.

Analyst Ratings Changes

Separately, Canaccord Genuity Group reissued a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a research note on Monday, March 17th.

Insider Buying and Selling at Bioventus

In other news, SVP Anthony D’adamio sold 4,380 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the transaction, the senior vice president now owns 118,178 shares in the company, valued at approximately $1,204,233.82. This represents a 3.57 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Mark Leonard Singleton sold 6,498 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total value of $66,214.62. Following the completion of the sale, the chief financial officer now owns 118,817 shares in the company, valued at $1,210,745.23. This represents a 5.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 24,208 shares of company stock worth $226,138 in the last quarter. 32.90% of the stock is currently owned by company insiders.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.